Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?
Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the best high-beta stocks to buy now.
Kymera Therapeutics Inc. (KYMR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 6,651,429 | $290,268,362 | +11% | 2.82% |
| 2. | VenBio Select Advisor Kurt Von Emster | 6,555,555 | $286,084,420 | +2% | 5.01% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,502,710 | $240,138,264 | +7% | 8.58% |
| 4. | Siren L.L.C. Raymond Debbane | 3,428,150 | $149,604,466 | +6% | 7.74% |
| 5. | Driehaus Capital Richard Driehaus | 933,890 | $40,754,960 | -21% | 0.33% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.00 | 58,780 | $2,586,320.00 | 353,412 | 2025-06-30 | Filing | |
| $44.00 | 115,783 | $5,094,452.00 | 2,219,858 | 2025-06-30 | Filing | |
| $44.00 | 142,604 | $6,274,576.00 | 2,798,795 | 2025-06-30 | Filing | |
| $44.00 | 600,309 | $26,413,596.00 | 6,117,295 | 2025-06-30 | Filing | |
| $44.00 | 55,191 | $2,428,404.00 | 534,134 | 2025-06-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $63.09 | 6,453 | $407,099.12 | 109,992 | 2025-10-15 | Filing | |
| $62.72 | 14,896 | $934,326.28 | 116,445 | 2025-10-15 | Filing | |
| $61.49 | 8,963 | $551,160.86 | 131,341 | 2025-10-15 | Filing | |
| $60.37 | 29,264 | $1,766,667.68 | 140,304 | 2025-10-15 | Filing | |
| $60.00 | 3,114 | $186,840.00 | 118,359 | 2025-10-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,455 | $2,063,353 | 0% | |
| 2. | 28,910 | $1,636,306 | 0.31% | |
| 3. | 9,000 | $509,400 | 0% | |
| 4. | 5,318 | $300,999 | 0.03% | |
| 5. | 4,571 | $258,719 | 0.02% |
News See All
10 Best High Beta Stocks to Buy Now
High-beta stocks often find themselves at the center of market rallies and sell-offs, amplifying gains during bullish stretches but carrying added risk when volatility returns.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone. My name is Olivia, and I will be your conference operator today. At this time, I would like to welcome you to the Kymera Therapeutics Second Quarter 2025 Results Call.
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds
As per the US Bank, the healthcare in the US exhibits a large and intricate ecosystem, which is characterized by size, complexity, and influence on the broader national economy.
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds.
Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader
B. Riley raised Kymera Therapeutics, Inc.’s (NASDAQ:KYMR) price target from $38 to $60, upgrading it from Neutral to Buy on June 3, 2025.
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT
On June 2, analyst Vikram Purohit from Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) with a price target of $49.
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating
On Monday, June 2, Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51
Earlier during the company's May 9 earnings call, Kymera indicated a strong financial position with $775 million in cash, which would extend the company's operational runway into H1 2028.